Understanding how extracorporeal photochemotherapy causes cell death

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to investigate the mechanisms of cell death induced by extracorporeal photochemotherapy (ECP) in patients with conditions such as cutaneous T-cell lymphoma and graft-versus-host disease. By collecting and treating leukocytes from patients, the study will analyze the type of cell death that occurs based on the cell type and the therapeutic context. The research will utilize various complementary analysis techniques to provide insights into the immunomodulatory effects of ECP and its potential to enhance treatment outcomes. The findings could help refine therapeutic regimens for patients undergoing ECP.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adult patients
* Treated with ECP for at least 1 month, for control of GVHD in hematopoietic cell allograft (acute or chronic GVHD), treatment and control of cellular or humoral rejection in solid organ transplantation (heart, lung, kidney) or in the treatment of cutaneous T-cell lymphoma

Exclusion Criteria:

* Subjects with limited legal capacity.
* Subjects judged by the investigator to be unlikely to comply with study procedures
* Subjects with no social security coverage.
* Pregnant women.
* Subjects still in the exclusion period of another study, or according to the national registry of clinical trial participants.

Where it's running

• Centre Hospitalier Universitaire de Besançon
  Besançon, France Recruiting

Study contacts

• Study coordinator: Charline VAUCHY, PhD
• Email: cvauchy@chu-besancon.fr
• Phone: +33381218875

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Long-term follow-up care for patients who received stem cell transplants

  This study looks at how people aged 10 to 80 who received stem cell transplants are doing over time to see how well they respond to treatment and if they have any long-term issues.

  Recruiting National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT00106925

• Low-dose liposomal amphotericin B to prevent invasive fungal infections in neutropenic children

  This study tests whether giving a fixed low dose of liposomal amphotericin B can prevent invasive fungal infections in children aged 3–17 who are severely neutropenic after hematopoietic stem cell transplantation or similar high-risk conditions.

  Recruiting Haikou Affiliated Hospital of Central South University Xiangya School of Medicine · Haikou, Hainan · NCT07725263

• Madecassoside tablets plus standard therapy for sclered scl-cGVHD after allo-HSCT

  This study tests whether adding madecassoside tablets to standard therapy can help people with scleral chronic graft-versus-host disease after stem cell transplant.

  Recruiting Phase 2 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT07606703

• T-cell–guided letermovir stopping after allogeneic stem cell transplant

  This tests whether using a CMV-specific T-cell blood test to decide when adult CMV-positive patients can stop letermovir after allogeneic stem cell transplant keeps them protected while avoiding unnecessary drug exposure.

  Recruiting Phase 4 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Beijing, Beijing Municipality and 11 other locations · NCT07569653

• Fatigue and thinking problems after allogeneic stem cell transplant (synapse damage or brain GVHD)

  This project uses PET scans and spinal fluid samples to try to find why people who had an allogeneic stem cell transplant have persistent fatigue and thinking problems.

  Recruiting Karolinska University Hospital · Stockholm · NCT07365696

• Fecal microbiota transplantation for steroid-refractory acute GI-GvHD

  This trial tests whether fecal microbiota transplantation can help adults with steroid-refractory acute gastrointestinal graft-versus-host disease after stem cell transplant.

  Recruiting Phase 2 Chang Gung Memorial Hospital · Taoyuan · NCT07364617

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.